🇺🇸 FDA
Patent

US 8278272

GLP-1, exendin-4, peptide analogs and uses thereof

granted A61KA61K38/00A61K38/2278

Quick answer

US patent 8278272 (GLP-1, exendin-4, peptide analogs and uses thereof) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Sep 27 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Oct 02 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 27 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
24
CPC classes
A61K, A61K38/00, A61K38/2278, A61K38/26, A61P